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Pancreatic Adenocarcinoma
in a Patient With
Multiple Endocrine
Neoplasia 1 Syndrome
To the Editor:
W e present the rare occurrence of aconcurrent pancreatic neuroendo-
crine tumor (pNET) and pancreatic ductal
adenocarcinoma (PDAC) in a patient with
multiple endocrine neoplasia 1 (MEN1)
syndrome. It is important for clinicians to
consider the possibility of PDAC in patients
with MEN1 because aggressive early sur-
gical intervention provides the only chance
of cure.
Multiple endocrine neoplasia 1 is char-
acterized by parathyroid adenomas, pNETs,
and anterior pituitary tumors.1 Multiple en-
docrine neoplasia 1Yassociated pNETs are
usually slowly progressive and associated
with low malignant potential. In the con-
text of MEN1, pancreatic NET size corre-
lates with prognosis and the presence of
metastases,2 and lesions of more than 2 cm
are associated with greater genetic instabil-
ity and malignant behaviour.3
The European Neuroendocrine Tu-
mour Society recommendations for man-
agement of pancreatic lesions in a patient
with MEN1 state that early diagnosis and
surgical excision of MEN1-related pNET
improve survival, preventing or delaying the
development of distant metastases.4 It is
mandatory to operate on MEN1-related non-
functioning pancreatic tumors with metas-
tases, size of more than 2 cm, or yearly
increased size of more than 0.5 cm. Man-
agement of pNETs of less than 2 cm is
controversial, current recommendation be-
ing intensive surveillance to avoid repeated
intervention where lesions are typically mul-
tiple and behave in an indolent fashion.
CASE HISTORY
A 46-year-old man was under sur-
veillance in a tertiary referral neuroen-
docrine tumor unit for a diagnosis of
MEN1 syndrome. Medical history included
Zollinger-Ellison syndrome with resection
of primary gastrinoma from the tail of the
pancreas, primary hyperparathyroidism, and
chronic hypercalcemia.
Fifteen years following his diagno-
sis of MEN1, he presented with anorexia,
nausea, and jaundice and was treated for
biliary sepsis. Computed tomography (CT)
scan and endoscopic retrograde cholangio-
pancreatography (ERCP) showed intrahepatic
and pancreatic duct dilation. Endoscopic
stent placement was performed, and the
patient improved.
Three months later, his symptoms
recurred, and he underwent a further ERCP
at which point a blocked stent was replaced
with symptomatic improvement. Biochemi-
cal testing showed an extremely high car-
bohydrate antigen 19-9 (CA-19-9) tumor
marker of 4520 U/mL (46 U/mL 2 months
previously). Cross-sectional imaging showed
a 2.8  2.2-cm mass in the head/uncinate
process of the pancreas with associated duct
obstruction. Cytological brushings from the
ERCP demonstrated synaptophysin immu-
nopositivity, indicating the presence of neu-
roendocrine tumor; however, gallium 68
DOTA octreotate positron emission tomog-
raphy (Ga-68 PET) scanning did not show
any uptake in the pancreas. Endoscopic ul-
trasound demonstrated the double duct sign
and confirmed a mass in the head of the
pancreas. In view of these findings, in asso-
ciation with a raised CA-19-9, a Whipple
pancreatoduodenectomy was performed.
Histology demonstrated a 30-mm moder-
ately differentiated ductal adenocarcinoma
of the head of the pancreas, invading to the
mucosal surface of the duodenum and peri-
pancreatic adipose tissue, pT3 N0M0 (stage
IIA). Also present was a concurrent 9-mm
well-differentiated grade 1 pNET, with 5 of
19 lymph nodes positive for metastatic neu-
roendocrine tumor (pT1 N1). Immunohis-
tochemistry of the pNET was positive for
chromogranin and synaptophysin, and
Ki-67 was less than 1%. Figure 1 illustrates
histopathologic features of both tumors.
DISCUSSION
In this case, the use of serum tumor
markers (a significantly raised CA-19-9)
FIGURE 1. A, Hematoxylin-eosinYstained section, original magnification 4: head of the pancreas with a moderately differentiated
pancreatic ductal-type adenocarcinoma (upper half of the picture) closely juxtaposed to a well-differentiated neuroendocrine
neoplasm of low grade (lower half of the picture). B, Immunohistochemistry for Ki-67, X4: the proliferative rate with Ki-67 is low
in the well-differentiated neuroendocrine neoplasm compared with the high proliferative rate seen in the pancreatic adenocarcinoma.
C, Immunohistochemistry for synaptophysin, X4: a diffuse and strong positivity is seen in the well-differentiated neuroendocrine
neoplasm, and complete negativity is seen in the adenocarcinoma.
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and negative functional imaging (Ga-68
PET) of the pancreatic mass raised the sus-
picion of an alternative diagnosis to the ex-
pected pNET.
CA-19-9 is the most frequently uti-
lized biochemical marker for pancreatic ade-
nocarcinoma, with median sensitivity for
diagnosis of 79% (70%Y90%) and speci-
ficity of 82% (68%Y91%).5 Specificity falls
in jaundice. Recommendations for evalua-
tion of suspected pancreatic adenocarcino-
ma involve endoscopic ultrasound and CT
assessment, and note that CA-19-9 is of
limited diagnostic value but of use to
guide treatment and follow-up.6
The use of functional and somatostatin
receptor imaging is important in the evaluation
of suspected neuroendocrine tumors; how-
ever, all modalities are limited by reduced
sensitivity for lesions of less than 1 cm.
Gallium 68 PET scan is more sensitive than
other modalities; however, its role in the
assessment of patients with MEN1 has not
yet been determined.7 In our case, lack of
uptake in the pancreas on Ga-68 PET despite
a 3-cm lesion being visualized on CT raised
the suspicion of nonneuroendocrine malig-
nancy. The small (9 mm) neuroendocrine
tumor was below the resolution threshold
of the Ga-68 PET and therefore was not
visualized.
CONCLUSIONS
We have presented a rare concurrence
of PDAC with pNET in a patient with
MEN1 syndrome. This case highlights the
importance of relevant imaging and bio-
chemical biomarkers and questions the
current practice of surveillance for small
pancreatic masses in patients with MEN1
syndrome.
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Masking Effect of Chronic
Pancreatitis in the
Interpretation of
Somatostatin Receptor
Positron Emission
Tomography in Pancreatic
Neuroendocrine Tumors
To the Editor:
T he pancreatic neuroendocrine tumors(pNETs) represent a small percentage
of all pancreatic tumors (1.3%), but their
incidence is rising.1 Neuroendocrine tumors
usually overexpress somatostatin receptors
on their cell surface; therefore, somatostatin
receptor imaging could be used to evalu-
ate these tumors. Somatostatin receptor
positron emission tomography/computed
tomography (SMSR-PET/CT) using different
somatostatin analogs (such as DOTANOC,
DOTATOC, DOTATATE) labeled with
gallium-68 is a valuable diagnostic tool
for staging and restaging patients with
NETs, including patients with pNET.2,3
We present a patient with a multifo-
cal pNET in whom the coexistence of
chronic pancreatitis has hampered the cor-
rect functional characterization of tumoral
lesions at SMSR-PET/CT.
CASE REPORT
A 49-year-old woman underwent
magnetic resonance imaging (MRI) for
onset of abdominal pain. Magnetic reso-
nance imaging showed a large encapsulated
exophytic mass arising from the pancreatic
tail, with heterogeneous hyperintensity on
axial T2-weighted image caused by necrotic
areas. Magnetic resonance imaging also
showed smaller lesions distributed in all
pancreatic segments that appear variably
hyperintense related to cystic compo-
nents in axial T2-weighted images (Fig. 1).
The patient underwent an endoscopic
ultrasonographyYguided fine-needle tissue
acquisition of the largest lesion in the pan-
creatic tail. Fine-needle aspiration cytology
showed small monomorphic cells form-
ing loosely structured groups positive for
chromogranin A at immunohistochemistry
and highly suspected for NET cells (Fig. 1).
Based on the morphologic suspicion of
a multifocal pNET, the patient underwent
SMSR-PET/CTwith gallium-68YDOTANOC
for staging. The SMSR-PET/CT images
showed diffuse and intense radiopharma-
ceutical uptake distributed in all the pan-
creatic segments, and a correct interpretation
and functional evaluation of the pancreatic
lesions detected at MRI were not possible.
This is an open access article distributed under
the Creative Commons Attribution License,
which permits unrestricted use, distribution, and
reproduction in any medium, provided the origi-
nal work is properly cited.
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